A Phase 1/2 Study of BGB-11417 Given Alone and With Carfilzomib and/or Dexamethasone to Treat Multiple Myeloma


Full Title

A Study of BGB-11417 Given Alone and in Combination With Carfilzomib and/or Dexamethasone, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in People With Multiple Myeloma


Researchers want to learn if BGB-11417 given alone or with dexamethasone and carfilzomib may help people with multiple myeloma. The people in this study have multiple myeloma that keeps growing after standard treatment. BGB-11417 blocks a protein called Bcl-2 that helps multiple myeloma cells to live and grow.

If you join this study, you will get one of these treatments:

  • BGB-11417 alone
  • BGB-11417 plus dexamethasone
  • BGB-11417 plus dexamethasone and a higher dose of carfilzomib
  • BGB-11417 plus dexamethasone and a lower dose of carfilzomib
  • Dexamethasone plus a higher dose of carfilzomib

Who Can Join

To join this study, there are a few conditions. You must:

  • Have multiple myeloma that came back or keeps growing after treatment.
  • Not have received more than 7 prior regimens of therapy for multiple myeloma.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information and to see if you can join this study, please contact the office of Dr. Malin Hultcrantz 646-608-3714.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID